Skip to main content

Table 2 Main outcomes in the full analysis set after 8 weeks

From: Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough variant asthma

 

M group

BF group

MBF group

Cough visual analogue scale (VAS)

n = 33

n = 33

n = 33

Baseline, median (IQR)

6.0 (5.0, 7.0)

5.0 (5.0, 9.0)

6.0 (5.0, 8.0)

Week 1, median (IQR)

4.0 (2.0, 5.0) *

3.0 (2.0, 5.0) *

2.0 (1.0, 5.0) *

Week 4, median (IQR)

2.0 (1.0, 4.0) *

2.0 (0.0, 3.0) *

1.0 (0.0, 2.0) *

Week 8, median (IQR)

2.0 (1.0, 4.0) *

1.0 (0.0, 2.0) *

1.0 (0.0, 2.0) *

Week 1 mean change from baseline, mean (95%CI)

 − 2.3 (− 3.1, − 1.5)

p < 0.001

 − 2.9 (− 3.7, − 2.1)

p < 0.001

 − 3.2 (− 4.0, − 2.4)

p < 0.001

Week 4 mean change from baseline, mean (95%CI)

 − 3.1 (− 3.9, − 2.3)

p < 0.001

 − 4.1 (− 4.9, − 3.3)

p < 0.001

 − 4.5 (− 5.3, − 3.7)

p < 0.001

Week 8 mean change from baseline, mean (95%CI)

 − 3.5 (− 4.3, − 2.7)

p < 0.001

 − 4.9 (− 5.7, − 4.1)

p < 0.001

 − 4.7 (− 5.5, − 3.9)

p < 0.001

Cough symptom score-daytime

n = 33

n = 33

n = 33

Baseline, median (IQR)

2.0 (2.0, 3.0)

2.0 (2.0, 3.0)

2.0 (2.0, 3.0)

Week 1, median (IQR)

2.0 (1.0, 2.0) *

2.0 (1.0, 2.0) *

1.0 (1.0, 2.0) *

Week 4, median (IQR)

1.0 (0.0, 2.0) *

1.0 (0.0, 2.0) *

1.0 (0.0, 2.0) *

Week 8, median (IQR)

1.0 (1.0, 2.0) *

1.0 (0.0, 2.0) *

1.0 (0.0, 1.0) *

Week 1 mean change from baseline, mean (95%CI)

 − 0.8 (− 1.1, − 0.4)

p < 0.001

 − 0.6 (− 1.0, − 0.2)

P = 0.003

 − 0.7 (− 1.1, − 0.3)

p < 0.001

Week 4 mean change from baseline, mean (95%CI)

 − 1.1 (− 1.5, − 0.7)

p < 0.001

 − 1.1 (− 1.5, − 0.7)

p < 0.001

 − 1.3 (− 1.7, − 0.9)

p < 0.001

Week 8 mean change from baseline, mean (95%CI)

 − 1.3 (− 1.7, − 0.9)

p < 0.001

 − 1.4 (− 1.8, − 1.0)

p < 0.001

 − 1.4 (− 1.8,1.0)

p < 0.001

Cough symptom score-night-time

n = 33

n = 33

n = 33

Baseline, median (IQR)

2.0 (1.0, 3.0)

2.0 (1.0, 3.0)

1.0 (1.0, 2.0)

Week 1, median (IQR)

1.0 (0.0, 2.0) *

1.0 (0.0, 1.0) *

1.0 (0.0, 1.0) *

Week 4, median (IQR)

1.0 (0.0, 1.0) *

1.0 (0.0, 1.0) *

0.0 (0.0, 1.0) *

Week 8, median (IQR)

1.0 (0.0, 1.0) *

0.0 (0.0, 1.0) *

0.0 (0.0, 1.0) *

Week 1 mean change from baseline, mean (95%CI)

 − 0.9 (− 1.3, − 0.5)

p < 0.001

 − 1.2 (− 1.54, − 0.78)

p < 0.001

 − 0.8 (− 1.2, − 0.4)

p < 0.001

Week 4 mean change from baseline, mean (95%CI)

 − 1.2 (− 1.6, − 0.8)

p < 0.001

 − 1.5 (− 1.9, − 1.1)

p < 0.001

 − 1.1 (− 1.5, − 0.7)

p < 0.001

Week 8 mean change from baseline, mean (95%CI)

 − 1.2 (− 1.6, − 0.8)

p < 0.001

 − 1.7 (− 2.1, − 1.3)

p < 0.001

 − 1.3 (− 1.7, − 0.9)

p < 0.001

  1. Values of VAS, CSS were presented as median (IQR); Values of the change in VAS, CSS were presented as mean (95%CI). M: montelukast alone; BF: budesonide/formoterol alone; MBF: montelukast plus budesonide/formoterol. VAS: visual analog scale; CSS: cough symptom score. VS baseline: #, p < 0.05; *, p < 0.01